In a groundbreaking new initiative, the Icahn School of Medicine at Mount Sinai, in partnership with the Uniformed Services University of the Health Sciences (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), has launched a transformative study named ORIGIN: Omics to Characterize Preclinical Stages of Non-Infectious Diseases. This ambitious project aims to harness cutting-edge molecular omics technologies to identify and intercept diseases years before symptoms surface, signaling a paradigm shift from reactive to proactive medicine.
The ORIGIN study is a multidisciplinary endeavor, blending expertise from ten different specialties within the Mount Sinai Health System to analyze an extraordinary resource: the Department of Defense Serum Repository (DoDSR). This repository contains millions of longitudinal blood samples collected from active-duty U.S. military personnel decades before disease onset. By leveraging advanced omics techniques—including proteomics, exposomics, metabolomics, and genomics—the researchers intend to detect early molecular signatures and unravel the biological pathways that foreshadow a wide spectrum of chronic diseases.
Dr. Jean-Frédéric Colombel, a professor of medicine and co-director of the Helmsley Inflammatory Bowel Disease Center at Mount Sinai, emphasized the potential of this research to revolutionize clinical care. “We’ve long envisioned a future where clinicians can anticipate disease and intervene preemptively,” he explains. ORIGIN builds on over ten years of collaboration with USU, where initial studies pinpointed molecular markers that appeared in blood years prior to inflammatory bowel disease diagnosis. The scale and scope now vastly surpass these preliminary efforts, with more than 25 diseases under simultaneous investigation.
ORIGIN’s research portfolio encompasses autoimmune conditions like rheumatoid arthritis, lupus, and multiple sclerosis; neurodegenerative disorders; several cancers including early-onset colon and lung cancer; and psychiatric conditions such as post-traumatic stress disorder (PTSD). The inclusion of such a diverse set of diseases reflects a novel approach, aiming to detect common molecular threads that may underlie seemingly disparate illnesses and to ultimately redefine disease classification through a molecular lens rather than by affected organ systems.
What sets ORIGIN apart is its integration within the Precision Immunology Institute at Mount Sinai (PrIISM), a unique consortium designed to dismantle traditional departmental silos. Cardiologists, immunologists, oncologists, neurologists, and environmental scientists collaborate closely, bringing their specialized knowledge to bear on shared pathological mechanisms. Such cross-disciplinary synergy, paired with state-of-the-art computational modeling, seeks to unravel complex biological networks that govern disease emergence and progression.
The use of military service members as subjects presents an unparalleled scientific opportunity. Because active-duty personnel undergo systematic, periodic health evaluations and blood draws, their archived samples in the DoDSR capture the dynamic biological milieu of individuals years before clinical symptoms arise. This longitudinal framework allows investigators to chart molecular changes over time and correlate them with future disease diagnoses, offering unprecedented insight into disease etiology and trajectory.
Of particular interest are environmental exposures unique to military contexts, such as contact with burn pits and per- and polyfluoroalkyl substances (PFAS), known colloquially as “forever chemicals” due to their persistence. These toxins are present at numerous U.S. military installations and could play crucial roles in modifying immune function or increasing cancer risk. ORIGIN’s exposomics approach endeavors to decode how such exposures alter human biology at the molecular level, potentially unveiling novel preventive strategies.
The data governance and analytic infrastructure supporting ORIGIN is state-of-the-art. USU data analysts meticulously curate and de-identify records, ensuring patient privacy while facilitating robust matched case-control comparisons. The integration of the Military Health System Data Repository with DoDSR’s biospecimens enables sophisticated bioinformatics analyses that correlate clinical outcomes with molecular data, charting the earliest molecular fingerprints of disease.
In the words of Dr. Daniel J. Adams, USU’s Principal Investigator for ORIGIN, “This collaboration advances our mission to optimize the readiness and health of our military community through groundbreaking scientific discovery.” The findings promise to inform not only military medicine but also have widespread civilian implications, particularly as the incidence of several targeted conditions accelerates in younger populations.
ORIGIN’s decade-spanning timeline and vast sample repository set the stage for longitudinal discovery. By analyzing specimens collected from 2003 through 2025, the consortium hopes to continually refine its understanding of preclinical biology and apply these insights to develop predictive biomarkers and precision interventions. The resulting molecular atlas of disease initiation could revolutionize clinical guidelines, drug development pipelines, and public health strategies.
The technical architecture of ORIGIN mirrors the complexity of the diseases under study. Proteomics explores the changing landscape of proteins that execute cellular functions; metabolomics reveals metabolic shifts that may signify cellular stress or dysfunction; genomics provides the foundational code underlying disease susceptibility; and exposomics integrates environmental variables. Together, these omics layers will be analyzed via advanced computational methods to generate predictive models capable of anticipating disease onset with unprecedented accuracy.
A key ambition of the project is to identify convergent molecular pathways shared among multiple diseases, paving the way for therapies that simultaneously target these common mechanisms rather than isolated symptoms. This systems biology perspective—facilitated by the collaborative spirit of PrIISM—has the potential to redefine medical paradigms and foster a new era of personalized, preventive healthcare applicable to both military and civilian populations worldwide.
Mount Sinai’s leadership role in this initiative aligns with its stature as a leading academic medical institution. The Health System’s enormous clinical and research infrastructure, including multiple hospitals, outpatient facilities, and a top-ranked medical school, provides a fertile environment for innovation. Furthermore, the robust tradition of integrating cutting-edge technologies such as artificial intelligence and large-scale data analytics underpins ORIGIN’s ambitious goals.
As the ORIGIN study progresses, its findings are poised to yield profound insights that extend beyond academic knowledge. They may lead to novel diagnostic platforms capable of identifying at-risk individuals early, new therapeutics designed to intercept disease processes before irreparable damage, and tailored preventive strategies that consider both genetic predispositions and environmental factors. Ultimately, ORIGIN aspires to transform medicine from a reactive model that treats symptoms to a predictive science that preserves health.
In summary, ORIGIN represents a visionary leap forward in biomedical research. By leveraging the unique longitudinal resources of the military, integrating multi-omics technologies, and fostering unprecedented interdisciplinary collaboration, the project stands to illuminate the molecular origins of chronic illnesses. This research will not only enhance the health and readiness of military personnel but also provide a blueprint for healthcare innovation benefiting global populations.
Subject of Research: People
Article Title: ORIGIN Initiative Pioneers Preclinical Omics Analysis to Predict and Prevent Chronic Diseases
News Publication Date: March 2, 2026
Web References:
Mount Sinai Health System: https://www.mountsinai.org
Mount Sinai on Facebook: https://www.facebook.com/mountsinainyc
Mount Sinai on Instagram: https://www.instagram.com/mountsinainyc
Mount Sinai on LinkedIn: https://www.linkedin.com/company/mountsinainyc
Mount Sinai on X (Twitter): https://twitter.com/mountsinainyc
Mount Sinai on YouTube: https://www.youtube.com/mountsinainy
Keywords: preventive medicine, gastroenterology, neurology, oncology, cardiology, multi-omics, proteomics, metabolomics, genomics, exposomics, molecular medicine, military medicine, chronic disease, inflammatory bowel disease, autoimmune diseases, early cancer detection, post-traumatic stress disorder, interdisciplinary collaboration, precision immunology
Tags: chronic disease preventionDepartment of Defense Serum Repository researchearly biomarkers identificationexposomics for health forecastinginterdisciplinary medical research collaborationmetabolomics and genomics integrationmilitary health longitudinal studiesmolecular omics technologiespreclinical disease detectionproactive healthcare modelsproteomics in medicinetransformative disease interception strategies
